NCT02620865View on ClinicalTrials.gov

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 21, 2021

Study Completion Date

June 21, 2021

Conditions
Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Antibody Therapy

Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV

DRUG

Fluorouracil

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

BIOLOGICAL

Sargramostim

Given SC

Trial Locations (1)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02620865 - BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter